Fig. 6
From: Tau PET imaging in neurodegenerative tauopathies—still a challenge
Hypothetical time course of pathological changes in Alzheimer’s disease (AD), in which biomarkers for amyloid-β become abnormal [cerebrospinal fluid (CSF) amyloid-β1–42 preceding PET], followed by abnormal tau (CSF p-tau preceding PET), neurodegeneration, and cognitive decline. Adapted with permission from Jack et al. [182] and 2013 [172], Nordberg [238], and McDade and Bateman [235]
